SCHEMBL10027286

SCHEMBL10027286

CCCCc1cnc2c(O)c(-c3ccc(OC)cc3)ccn2c1=O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DCTPP1 Q9H773 1/20 0.42
▸ HDAC4 P56524 1/20 0.40
▸ HDAC2 Q92769 1/20 0.40
▸ HDAC8 Q9BY41 1/20 0.40
▸ CASP3 P42574 1/20 0.38
▸ SENP8 Q96LD8 1/20 0.38
▸ SENP7 Q9BQF6 1/20 0.38
▸ SENP6 Q9GZR1 1/20 0.38
▸ APLNR P35414 6/20 0.37
▸ ALDH1A1 P00352 1/20 0.37
▸ LMNA P02545 1/20 0.37
▸ HPGD P15428 1/20 0.37
▸ MEN1 O00255 2/20 0.36
▸ KMT2A Q03164 2/20 0.36
▸ ELANE P08246 1/20 0.36
▸ CTSG P08311 1/20 0.36
▸ GAA P10253 1/20 0.36
▸ ADORA2A P29274 2/20 0.36
▸ ADORA3 P0DMS8 2/20 0.36
▸ ADORA2B P29275 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10027290 0.88 SMARCA2 (0.46) DCTPP1APLNRALDH1A1HPGDKMT2A
SCHEMBL10027235 0.78 MAPT (0.36) ALDH1A1LMNAHPGDMEN1KMT2A
SCHEMBL14161893 0.78 FLT3 (0.53) DCTPP1CASP3SENP8SENP7SENP6
SCHEMBL17808760 0.74 LMNA (0.36) ALDH1A1LMNAHPGDMEN1KMT2A
SCHEMBL10027234 0.73 MAPT (0.43) ALDH1A1LMNAHPGDELANECTSG
SCHEMBL19361118 0.72 AURKA (0.36) LMNATP53MAPTGSK3AGSK3B
SCHEMBL10027311 0.71 MAPT (0.36) ALDH1A1LMNAHPGDGAATP53
SCHEMBL10027291 0.70 MAPT (0.36) LMNATP53MAPT
SCHEMBL17808730 0.70 PRKCQ (0.34) LMNAMEN1KMT2AGAAMAPT
SCHEMBL27390516 0.68 MEN1 (0.47) CASP3SENP8SENP7SENP6LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8163760-B2 Use of pyridopyrimidine compounds in the treatment of gliomas PRANA BIOTECHNOLOGY LIMITED (AU) 2012-04-24 — — US disclosed
US-8163760-B2 Use of pyridopyrimidine compounds in the treatment of gliomas PRANA BIOTECHNOLOGY LIMITED (AU) 2012-04-24 — — US disclosed
US-20100069393-A1 METHOD OF TREATMENT AND AGENTS USEFUL FOR SAME PRANA BIOTECHNOLOGY LIMITED (AU) 2010-03-18 — — US disclosed
US-20100069393-A1 METHOD OF TREATMENT AND AGENTS USEFUL FOR SAME PRANA BIOTECHNOLOGY LIMITED (AU) 2010-03-18 — — US disclosed
WO-2007147217-A1 METHOD OF TREATMENT OF GLIOMA BRAIN TUMOUR PRANA BIOTECHNOLOGY LIMITED (AU) 2007-12-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100069393-A1 METHOD OF TREATMENT AND AGENTS USEFUL FOR SAME MGMT, DHFR, IDH2 DCTPP1 1103/4885HDAC4 413/4885HDAC2 668/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback